Lymph Node Ratio as Determined by the 7th Edition of the American Joint Committee on Cancer Staging System Predicts Survival in Stage III Colon Cancer
Lymph Node Ratio as Determined by the 7th Edition of the American Joint Committee on Cancer Staging System Predicts Survival in Stage III Colon Cancer
复制标题
DOI：
10.1002/jso.21830
复制
发表时间：
2011-04-01
影响因子：
2.5
通讯作者：
Moon, Hong Young
中科院分区：
文献类型：
--
作者：
Hong, Kwang Dae;Lee, Sun Il;Moon, Hong Young
背景和目标：本研究的目的是评估淋巴结比率（LNR）在III期结肠癌的预后有用性使用第7版的美国癌症联合委员会（AJCC）staging system.Method：我们分析了130例连续III期结肠癌患者的数据。Kaplan-Meier和考克斯比例风险模型分析对预后的影响。结果：四分位数分析表明LNR为0.1638是预测无病生存（DFS）的最佳截断值。6例患者为IIIA期疾病，102例患者为IIIB期疾病，22例患者为IIIC期疾病。对于IIIB期疾病患者，LNR = 0.1638（N = 15）的3年DFS分别为79.0%和50.0%（P = 0.015）。对于IIIC期疾病患者，LNR = 0.1638（N = 16）的3年DFS分别为100%和28.6%（P = 0.03）。作者发现，当按LNR分层时，第7 AJCC IIIB期和IIIC期患者在DFS方面是异质性组，并建议设计一种基于LNR的算法，以纳入第七届AJCC分期系统。《肿瘤外科杂志》2011; 103：406-410. (C)2010 Wiley-Liss，Inc.
Background and Objectives: The aim of this study was to evaluate the prognostic usefulness of the lymph node ratio (LNR) in stage III colon cancer using the 7th edition of the American Joint Committee on Cancer (AJCC) staging system.Method: We analyzed data from 130 consecutive patients with stage III colon cancer. Kaplan-Meier and Cox proportional hazard model analyses were used to evaluate prognostic effects.Results: Quartile analysis indicated that an LNR of 0.1638 was the best cut-off value with regard to predicting disease-free survival (DFS). Six patients had stage IIIA disease, 102 patients had stage IIIB disease, and 22 patients had stage IIIC disease. For patients with stage IIIB disease, the 3-year DFS for an LNR of = 0.1638 (N = 15) was 79.0% and 50.0%, respectively (P = 0.015). For patients with stage IIIC disease, the 3-year DFS for an LNR of = 0.1638 (N = 16) was 100% and 28.6%, respectively (P = 0.03).Conclusions: The authors found that 7th AJCC stage IIIB and stage IIIC patients are heterogeneous groups with respect to DFS, when stratified by LNR, and suggest that an LNR-based algorithm be devised for incorporation into the 7th AJCC staging system. J. Surg. Oncol. 2011; 103: 406-410. (C) 2010 Wiley-Liss, Inc.